Vocabria

Generic name: Cabotegravir
Drug class: Integrase strand transfer inhibitor

Usage of Vocabria

Vocabria is an antiviral medicine that prevents human immunodeficiency virus (HIV) from multiplying in your body. HIV is the virus that can cause acquired immunodeficiency syndrome (AIDS).

Vocabria tablets are used together with another antiviral called rilpivirine for treatment of HIV in people 12 years and older weighing at least 77 pounds (35 kg) to replace their current HIV medicines.

Vocabria is also used in HIV negative patients to lower the chance of getting HIV infection in people 12 years and older weighing at least 77 pounds (35 kg). You must be HIV negative to start and keep using Vocabria to lower the chance of getting HIV infection.

Vocabria and rilpivirine are given as a daily "lead-in dose" to help determine that you can safely use a combination form of these medicines given as an injection.

Vocabria and rilpivirine may also be given short-term in place of the injectable combination if you plan to miss an injection by more than 7 days.

Vocabria and rilpivirine is for use in adults who have already used other antiviral HIV medications that have controlled their viral load. These medicines are not a cure for HIV or AIDS.

Vocabria side effects

Get emergency medical help if you have signs of an allergic reaction to Vocabria: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Stop using this medicine and get medical help at once if you have a skin rash with any of the following symptoms:

extreme tiredness, fever, not feeling well;

muscle or joint pain;

blisters or sores in or around your mouth;

red or puffy eyes; or

swelling in your face or mouth, trouble breathing.

Vocabria may cause serious side effects. Call your doctor at once if you have:

unusual changes in mood such as feeling sad, hopeless, anxious, or restless;

suicidal thoughts or actions; or

liver problems - loss of appetite, nausea, vomiting, stomach pain (upper right side), dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).

Common Vocabria side effects of Vocabria may include:

nausea;

abnormal dreams;

feeling anxious;

headache; or

sleep problems.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Vocabria

You should not use Vocabria if you are allergic to Cabotegravir.

Many drugs can interact and cause dangerous effects. Some drugs should not be used together with Vocabria. Your doctor may change your treatment plan if you also use:

certain antibiotics - rifabutin, rifampin, rifapentine; or

seizure medicine - Carbamazepine, oxcarbazepine, phenobarbital, phenytoin.

To make sure Vocabria is safe for you, tell your doctor if you have ever had:

a skin rash or an allergic reaction after using medicine that contains cabotegravir;

liver disease; or

mental illness.

Tell your doctor if you are pregnant or plan to become pregnant. It is not known whether cabotegravir will harm an unborn baby. However, HIV can be passed to your baby if the virus is not controlled during pregnancy. Your name may be listed on a registry to track any effects of cabotegravir on the baby.

Women with HIV or AIDS should not breastfeed a baby. Even if your baby is born without HIV, the virus may be passed to the baby in your breast milk.

Vocabria is not approved for use by anyone younger than 12 years old or weighing less than 77 pounds (35 kilograms).

Relate drugs

How to use Vocabria

Usual Adult Dose for HIV Infection:

30 mg orally once a day Comments: -To be taken with rilpivirine tablets (25 mg orally once a day) -Oral lead-in should be used for about 1 month (at least 28 days) to assess tolerability of cabotegravir before the initiation of cabotegravir-rilpivirine IM. -The last oral dose should be administered on the same day injections with cabotegravir-rilpivirine IM are started. -If a patient plans to miss a scheduled cabotegravir-rilpivirine IM injection by more than 7 days, this drug may be used with rilpivirine tablets once a day to replace up to 2 consecutive monthly injection visits. ---The first dose of oral therapy should be administered about 1 month after the last injection dose of cabotegravir-rilpivirine IM and continued until the day injection dosing is restarted. ---The manufacturer product information for cabotegravir-rilpivirine IM should be consulted regarding resumption of monthly injection dosing. Uses: In combination with rilpivirine tablets, for short-term treatment of HIV-1 infection in patients who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known/suspected resistance to either cabotegravir or rilpivirine, as: -Oral lead-in to assess tolerability of this drug before starting cabotegravir-rilpivirine IM -Oral therapy for patients who will miss planned injection dosing with cabotegravir-rilpivirine IM

Warnings

Tell your doctor about all your current medicines and any you start or stop using. Many drugs can interact, and some drugs should not be used together.

What other drugs will affect Vocabria

Some antacids can make Vocabria much less effective when taken at the same time. If you take an antacid, take it at least 2 hours before or 4 hours after you take Vocabria.

Other drugs may interact with cabotegravir, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.